Company / Working Capital
FATE THERAPEUTICS INC Working Capital History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Working Capital
$172.6M
FY2025
5-year range
$172.6M / $552.1M
FY2021-FY2025
Trend
-31.9%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Working Capital has declined for 4 consecutive years, from $552M in FY2021 to $173M in FY2025.
Based on SEC 10-K filings.
$173M in FY2025 with a 5-year CAGR of -15.8%.
Declined from $292M to $173M over the past 2 years.
Working Capital over time
Growth rates
- 3-Year CAGR
- -23.7%
- 5-Year CAGR
- -15.8%
- 10-Year CAGR
- -
Key checks
Key Insights
- FATE THERAPEUTICS INC's working capital has declined for 4 consecutive years.
- 5-year CAGR of -15.8%, indicating a declining trend.
- In FY2025, working capital decreased 31.9% year-over-year.
- Peak working capital was recorded in FY2021.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 632.81 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Working CapitalValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $172.6M | -31.9% |
| FY2024 | $253.4M | -13.4% |
| FY2023 | $292.4M | -24.6% |
| FY2022 | $388.0M | -29.7% |
| FY2021 | $552.1M | +35.1% |
| FY2020 | $408.8M | +105.1% |
| FY2019 | $199.3M | +12.0% |
| FY2018 | $177.9M | +94.4% |
| FY2017 | $91.5M | +17.2% |
| FY2016 | $78.1M | +49.7% |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026